Ex vivo human model designed to evaluate the vaccine potential of a composition

EP4469797A1Pending Publication Date: 2024-12-04GENOSKIN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023702007
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-27
Filing Date
2023-01-27
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Current methods for evaluating the vaccine potential of compositions rely on animal models, which are inadequate for predicting human responses, as they do not accurately reflect human immune reactions and can induce unnecessary inflammation.

Method used

An ex vivo human skin model is developed that allows for the subcutaneous injection of compositions, enabling the assessment of antigen-presenting cell activation and migration, as well as cytokine expression profiles to determine vaccine potential without animal testing.

Benefits of technology

This model effectively evaluates the vaccine potential of compositions by simulating human immune responses, providing a reliable and humane method to assess both immune activation and inflammatory potential, thus overcoming the limitations of animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000025
    Figure 000025
  • Figure 000026
    Figure 000026
  • Figure IMGF000009_0001
    Figure IMGF000009_0001
Patent Text Reader

Abstract

The present invention relates to an ex vivo method designed to evaluate the vaccine potential of a composition, the method comprising the steps of: ia) transcutaneously administering the composition to a skin explant comprising the epidermis, the dermis and the epidermal appendages, as well as a thickness of at least 5 millimetres of hypodermis; ib) determining the activation status of the antigen-presenting cells within the skin explant; and ii) determining the vaccine potential of the composition.
Need to check novelty before this filing date? Find Prior Art

Description

Ex vivo human model intended for evaluating the vaccine potential of a composition

[0001] This patent application claims priority from French patent application FR2200690 filed on January 27, 2023, which is hereby incorporated by reference. technical field

[0002] The present invention relates to the field of vaccination and proposes, more specifically, the first ex vivo human model allowing the determination of the vaccine potential of a composition. Previous art

[0003] To ensure its protection, the human body has 2 types of defense mechanisms: innate immunity and adaptive immunity.

[0004] Innate immunity allows the body to defend itself against infectious agents immediately. Conversely, adaptive (or acquired) immunity provides the body with protection later, but more lasting.

[0005] In connection with innate immunity, this response is immediate upon exposure to an infectious agent. Furthermore, this response is independent of the antigens of that infectious agent. In addition, this immune response is of comparable intensity with each subsequent exposure to the same infectious agent.

[0006] Adaptive immunity requires a learning phase for the body. Following the interaction between an infectious agent and innate immunity, adaptive immunity becomes active in lymphoid tissues, especially in the lymph nodes and spleen. Several mechanisms are then involved:

[0007] 1- The antigen (infectious agent) directly activates B lymphocytes, which possess specific receptors. The activated B lymphocytes then become plasma cells, which will secrete specific antibodies for the destruction of the antigen (humoral immunity).

[0008] 2 - The antigen (infectious agent) is presented to T lymphocytes by antigen-presenting cells (e.g., dendritic cells). The antigen-presenting cells activate the T lymphocytes, which differentiate into: • Cytotoxic T lymphocytes (CD8+), which destroy infected cells (cellular immunity); • Helper T lymphocytes (CD4+), or T follicular helper cells, which stimulate B lymphocytes to produce a greater quantity of antibodies and memory cells, which will then lodge in the bone marrow.

[0009] Adaptive immunity therefore requires, after a 1 er It takes at least 2 to 3 weeks for this immunity to develop after contact with an infectious agent. This immunity is dependent on and specific to the antigens of an infectious agent. The immune response associated with this immunity increases in intensity following each contact with the same infectious agent.

[0010] The vaccination strategy aims to develop adaptive immunity using antigens from a specific infectious agent. However, obtaining a composition with good vaccine potential is a complex undertaking. First and foremost, this composition must allow for the proper activation of antigen-presenting cells, thereby inducing a specific immune response. Simultaneously, it is desirable that this composition not induce an excessively strong inflammatory response (i.e., limited mast cell degranulation).

[0011] Today, the only option for estimating the vaccine potential of a composition lies in animal models, which nevertheless leave many unknowns regarding the actual vaccine potential of a given composition in humans.

[0012] Therefore, there is a need for a tool that would allow for the easy and rapid determination, without resorting to animals, of the vaccine potential in humans of an injectable composition. Description of the invention

[0013] The inventors previously developed an ex vivo model of human skin which allows testing the subcutaneous injection of a solution without resorting to animals.

[0014] The inventors had also demonstrated that not only were mast cells stably present in this human skin model, but that they also remained functional with an intact degranulation capacity.

[0015] Now, the inventors have demonstrated that antigen-presenting cells are also present in this skin model and, moreover, that they exhibit an intact maturation capacity. This result was all the more unexpected since, following the culturing of human skin, the presenting cells were described as migrating out of the skin explant into the culture medium (LENZ et al., J. Clin. Invest., vol.92, p:2587-2596, 1993; POPE et al., J. Invest. Dermatol., vol.104(1), p:11-17, 1995; RATZINGER et al., J. Immunol., vol.168, p:4361-4371; 2002; KIVINEN et al., Experimental Dermatology, vol.12, p:53-60, 2003).

[0016] In light of this discovery, the inventors had the idea of ​​adapting this model to determine the vaccine potential of a composition by following the response of these antigen-presenting cells after the injection of this composition.

[0017] The inventors have finally demonstrated that this new model effectively makes it possible to determine the vaccine potential of an ex vivo composition, which constitutes a major advance for this technological field.

[0018] Also, a first object of the invention relates to an in vitro process for determining the vaccine potential of a composition comprising the steps of:

[0019] ia) transcutaneous administration of the composition to a skin expiant comprising the epidermis, dermis and epidermal annexes as well as a thickness of at least 5 millimeters of hypodermis;

[0020] ib) determination of the activation status of antigen-presenting cells within the skin explant; and

[0021] ii) determination of the vaccine potential of the composition.

[0022] According to a preferred embodiment, the process further includes a step ic) of determining the possible migration of antigen-presenting cells within the skin expiry.

[0023] According to another preferred embodiment, the process further includes a step id) of determining the expression profile of immune system-related genes, including cytokines, within the skin expiry and in that step ii) further allows the determination of the inflammatory potential associated with this same composition.

[0024] According to a final preferred embodiment, the process further includes a step ie) of determining the level of mast cell degranulation within the skin expiry and in that step ii) also allows determining the inflammatory potential associated with this same composition. Description of the drawings

[0025] [Fig 1] represents the different populations of antigen-presenting cells (APCs) and the markers associated with each of them. Detailed description of the invention

[0026] By "vaccine composition" we mean a composition comprising at least one antigen (lipid, carbohydrate, protein or even peptide) or a nucleic acid encoding at least one antigen and, potentially, at least one adjuvant.

[0027] By "skin expiatory", we mean a fragment of skin which includes, in addition to the epidermis, the dermis and the epidermal appendages, a thickness of at least 5 mm of hypodermis (preferably between 5 and 15 mm of hypodermis and, even more preferably, between 5 and 10 mm of hypodermis).

[0028] Epidermal appendages include hair follicles, sebaceous glands, and sweat glands. The hypodermis is the layer of tissue located immediately beneath the dermis of the skin. The hypodermis is a loose connective tissue. which is richly vascularized and also contains adipose tissue and immune cells.

[0029] If this skin expungement is taken from a mammal, either human or pig could be used. However, given the preferred application of the process according to the invention, human skin expungement will be chosen instead.

[0030] In connection with the origin of the skin explant, it can come from a plastic surgery procedure from any part of the body, including plastic surgery of the abdomen, breasts, buttocks, back, or even, why not, the scalp or any other part of the body containing skin.

[0031] The skin explant is prepared as described in international application WO 2019 / 170281.

[0032] Specifically, this skin expiant, with the exception of the epidermis, was embedded in a liquid matrix capable of solidifying, such as blood plasma, a blood plasma-derived solution (e.g., a blood plasma dilution in physiological buffer, in particular a blood plasma dilution of at least 10%, 20%, 30%, or even at least 40% (weight / total weight of the matrix)), a fibrinogen solution, a collagen solution, a gelatin solution, synthetic polymer solutions, natural polymer solutions (e.g., agarose (low / low melting point agarose or agar-agar), starch, polysaccharides), and mixtures thereof. For further details regarding the matrices capable of solidifying and the methods for embedding the skin expiants within them, see European Patent No. EP 2 882290 B1. Now, these matrices and methods described in paragraphs

[0024] to

[0042] and

[0067] to

[0080] of European patent no. EP 2 882290 Bl.

[0033] In the case of a cylindrical skin expiant, we will therefore opt for a skin expiant with a diameter between 10 mm and 50 mm, preferably between 1 mm and 40 mm.

[0034] Advantageously, the skin explant is positioned within an insert that can take various forms, including a suspended insert or an insert on stilts. A suspended insert is now the preferred option. The base of this insert consists of a porous membrane with a diameter of... The membrane's porosity should be between 5 and 40 mm, and preferably between 9.5 and 30 mm. It must prevent the liquid matrix from passing through before solidification. Typically, this porous membrane will have a porosity between 0.4 and 8 µm, preferably between 0.4 and 1.5 µm, with 0.8 to 1.2 µm being the preferred range. As for the material, a porous membrane made of polyethylene terephthalate (PET), nitrocellulose, or polycarbonate is suitable.Finally, and as an example of such inserts, we can cite those supplied by the companies NUNC, CORNING, BECTON DICKINSON (BD FALCON), MILLIPORE (MILLICELL), which can take the form of inserts with polycarbonate, PET or nitrocellulose membrane, which are pre-packed in multi-well plates for 6, 8, 12 or 24-well culture plates, and whose membrane porosity can vary from 0.4 and 8pm.

[0035] Transcutaneous administration refers to the administration of a composition that allows it to penetrate the skin barrier. Such transcutaneous administration can be done subcutaneously (i.e., by subcutaneous injection (a needle), transdermally (via a simple patch or one with microneedles), or topically.

[0036] Topical administration means applying the composition to be tested to the epidermis of the skin explant in the form of a cream or gel, for example.

[0037] Subcutaneous administration refers to a subcutaneous injection, which is administered into the hypodermis of the skin explant using a needle, hence the name "hypodermic" injection. This type of injection, well-known to those skilled in the art, generally requires creating a skin fold with the fingers, and the subcutaneous injection is then administered into this fold.

[0038] By "transdermal administration", we also speak of "transepidermal administration", we mean an administration which uses a patch incorporating or not microneedles (which microneedles may be biodegradable).

[0039] According to a preferred embodiment, step ia) consists of subcutaneous or transdermal administration of a composition comprising the substance in a skin expiant.

[0040] The composition in question is a test composition which is in liquid form. Advantageously, the volume of this composition is between 10 lp and 1 ml, preferably between 10 lp and 500 lp and, particularly preferably, between 10 lp and 200 lp.

[0041] The needle used to inject the composition is typically long enough to reach the hypodermis. Therefore, needles with a length of 10 mm or more are preferred. Examples of such needles include those with lengths of 12, 16, 20, 25, 30, 35, 40, or 45 mm. Advantageously, the needle should be between 16 and 45 mm long, preferably between 20 and 40 mm. The diameter of the needle to be used can be easily determined by a person skilled in the art, based on their general knowledge. Typically, such hypodermic needles are of the 18G, 19G, 20G, 21G, 22G, 23G, 25G, 26G, 27G, 28G, 29G, 30G or even 31G type.

[0042] This injection step can be performed by an experimenter, who applies pressure to the skin to create a fold and thus facilitate subcutaneous injection. Alternatively, this injection step can also be performed using an automated injection device. Typically, the device delivers an injection at a predetermined depth relative to the epidermal surface, resulting in a subcutaneous injection.

[0043] Advantageously, only one step ia) of administration of a composition is carried out by skin expiant.

[0044] Step ib) of determining the activation status of immune cells and in particular antigen-presenting cells within the skin expiry is carried out by monitoring the expression of activation markers within these cells.

[0045] To achieve this, well-known immunohistochemical methods can be used, which involve fixing a skin Texplant, embedding the expiant (e.g., paraffin, OCT, EPON) before preservation, and finally preparing histological sections of the embedding block. Details of such methods are described, for example, in "Immunohistochemistry: Basics and Methods" by Igor Buchwalow (Springer Publishers).

[0046] Methods such as flow cytometry and BULK and SINGLE-CELL type transcriptomic analyses can also be used.

[0047] Usable histological sections can be very thick, up to 500 µm. Advantageously, the histological section will thus have a thickness between 1 and 500 µm. It is now also possible to use sections with more conventional dimensions, with a thickness between 2 and 25 µm.

[0048] Antigen-presenting cells are defined as cells expressing the CD45 and HLA-DR markers. For further details, the complete set of antigen-presenting cells is described in Figure 1.

[0049] Advantageously, antigen-presenting cells (APCs) are selected from dermal cDCl cells, dermal Langerin' cDC2 cells, Langerin' cDC2 cells 4 dermal and Langerhans cells (LCs). The detailed profile of markers expressed by these cells is given in Table 1 below.

[0050] [Table 1]

[0051] Activation markers refer to all the markers described in Table 2.

[0052] [Table 2]

[0053] An antigen-presenting cell is considered activated when at least 2 activation markers are overexpressed in that cell, preferably at least 3 activation markers and, particularly preferably, at least 5 activation markers.

[0054] Overexpression of an activation marker is defined as an increase in its expression of at least 20%, and preferably at least 30%, compared to the baseline expression level. Such an increase is measured between the antigen-presenting cells of two skin expiants from the same donor, only one of which was injected with the composition whose vaccine potential is to be determined, and the other with a control composition (water for injection or PBS).

[0055] Step ic) of determining the possible migration of antigen-presenting cells within the skin explant is also carried out by well-known immunohistochemical methods as described previously.

[0056] To do this, we determine whether or not the antigen-presenting cells have relocated to the vicinity of blood and / or lymphatic vessels. Determining such relocation can be done simply because blood and lymphatic vessels have characteristic structures that are easily identifiable within the histological section of the skin explant.

[0057] Relocalization of antigen-presenting cells near or away from blood and / or lymphatic vessels means an increase of at least 10% in the population of antigen-presenting cells near blood and lymphatic vessels, preferably at least 20%.

[0058] Step ii) of determining the vaccine potential of the composition can then be simply carried out with regard to the result of steps ib) and, possibly ic).

[0059] Thus, it will be possible to determine if the composition has vaccine potential with regard to an increase in the activation of antigen-presenting cells.

[0060] Thus, a composition associated with an activation of at most 10% of antigen-presenting cells will have a low, or even zero, vaccine potential.

[0061] Conversely, a composition associated with an activation of at least 40% of antigen-presenting cells will exhibit high vaccine potential.

[0062] Preferably, an increase of at least 20% in at least two of the activation markers (HLA-DR, CD80, CD86, CD83, CD40 and CCR7) is observed in antigen-presenting cells in the case of a composition associated with high vaccine potential.

[0063] Finally, a composition associated with an intermediate activation of antigen-presenting cells and not exceeding either of the two previous thresholds will present an intermediate, or even moderate, vaccine potential.

[0064] Thus, it will also be possible to specify the vaccine potential of the composition with regard to a possible migration of antigen-presenting cells.

[0065] Thus, a composition associated with a relocation of at most 2% of antigen-presenting cells near blood and / or lymphatic vessels will have a low, or even zero, vaccine potential.

[0066] Conversely, a composition associated with a relocation of at least 10% of antigen-presenting cells to the vicinity of blood and / or lymphatic vessels will exhibit high vaccine potential.

[0067] For control purposes, the same steps ia), ib), ic) may be carried out with a negative control (e.g. PB S) and / or with a composition including a positive control corresponding to a composition known to have high vaccine potential.

[0068] According to a preferred embodiment, the process further includes a step id) determination of the expression profile of genes related to the immune system within the skin explant.

[0069] Examples of genes linked to the immune system, and in a non-exhaustive manner, include the following:

[0070] ABCB1, ABCF1, ABL1, ACKR4, ADA, ADGRE5, AHR, AICDA, AIRE, ALAS1, APP, ARG1, ARG2, ARHGDIB, ATG10, ATG12, ATG16L1, ATG5, ATG7, ATM, B2M, B3GAT1, B ATF, BATF3, BAX, BCAP31, BCL10, BCL2, BCL2L11, BCL3, BCL6, BID, BLNK, BST1, BST2, BTK, BTLA, C1QA, C1QB, C1QBP, CIR, CIS, C2, C3, C4A / B, C4BPA, C5, C6, C7, C8A, C8B, C8G, C9, CAMP, CARD9, CASP1, CASP10, CASP2, CASP3, CASP8, CCL11, CCL13, CCL15, CCL16, CCL18, CCL19, CCL2, CCL20, CCL22, CCL23, CCL24, CCL26, CCL3, CCL4, CCL5, CCL7, CCL8, CCND3, CCR1, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL2, CD14, CD160, CD163, CD164, CD19, CD1A, CD1D, CD2, CD209, CD22, CD24, CD244, CD247, CD27, CD274, CD276, CD28, CD34, CD36, CD3D, CD3E, CD3EAP, CD4, CD40, CD40LG, CD44, CD45R0, CD45RA, CD45RB, CD46, CD48, CD5, CD53, CD55, CD58, CD59, CD6, CD7, CD70, CD74, CD79A, CD79B, CD80, CD81, CD82, CD83, CD86, CD8A, CD8B, CD9, CD96, CD99, CDH5, CDKN1A, CEACAM1, CEACAM6, CEACAM8, CEBPB, CFB, CFD, CFH, CFI, CFP, CHUK, CIITA, CISH, CLEC4A, CLEC4E, CLEC5A, CLEC6A, CLEC7A,CLU, CMKLR1, CRI, CR2, CRADD, CSF1, CSF1R, CSF2, CSF2RB, CSF3R, CTLA4, CTLA4-TM, CTNNB1, CTSC, CTSG, CTSS, CUL9, CX3CL1, CX3CR1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL2, CXCL8, CXCL9, CXCR1, CXCR2, CXCR3, CXCR4, CXCR6, CYBB, DEFBI, DEFB103A, DEFB103B, DEFB4A, DPP4, DUSP4, EBI3, EDNRB, EEF1G, EGR1, EGR2, ELP1, ENTPD1, ​​EÛMES, ETS1, FADD, FAS, FCAR, FCER1A, FCER1G, FCGR1A / B, FCGR2A, FCGR2A / C, FCGR2B, FCGR3A / B, FCGRT, FKBP5, FN1, FOXP3, FYN, G6PD, GAPDH, GATA3, GBP1, GBP5, GFI1, GNLY, GP1BB, GPI, GPR183, GUSB, GZMA, GZMB, GZMK, HAMP, HAVCR2, HFE, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HPRT1, HRAS, ICAM1, ICAM2, ICAM3, ICAM4, ICAM5, ICOS, ICOSLG, IDO1, IFI16, IFI35, IFIH1, IFIT2, IFITM1, IFNA1 / 13, IFNA2, IFNAR1, IFNAR2, IFNB1, IFNG, IFNGR1, IFNL1, IFNL2, IFNL2 / 3, IGF2R, IKBKB, IKBKE, IKBKG, IKZF1, IKZF2, IKZF3, IL10, IL I ORA, IL11RA, IL12A, IL12B, IL I2RB I, IL13, ILI 3RA I, IL15, IL16, IL17A, IL17BIL17F, IL18, IL18R1, IL18RAP, IL19, ILIA, IL1B, IL1R1, IL1R2, ILIRAP, IL1RL1, IL I RL2. IL1RN, IL2, IL20, IL21, IL21R, IL22, IL22RA2, IL23A, IL23R, IL26, IL27, IL2RA, IL2RB, IL2RG, IL3, IL32, IL4, IL4R, IL5, IL6, IL6R, IL6ST, IL7, IL7R, IL9, ILF3, IRAKI, IRAK2, IRAK3, IRAK4, IRF1, IRF3, IRF4, IRF5, IRF7, IRF8, IRGM, ITGA2B, ITGA4, ITGA5, ITGA6, ITGAE, ITGAL, ITGAM, ITGAX, ITGB1, ITGB2, ITLN1, ITLN2, JAK1, JAK2, JAK3, KCNJ2, KIR3DL1, KIR3DL2, KIR3DL3, KIR Activating Subgroup l, KIR_Activating_Subgroup_2, KIR Inhibiting Subgroup l, KIR_Inhibiting_Subgroup_2, KIT, KLRA1P, KLRB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, KLRF1, KLRF2, KLRG1, KLRG2, KLRK1, LAG3, LAIR1, LAMP3, LCK, LCP2, LEF1, LGALS3, LIF, LIERAI, LILRA2, LILRA3, LILRA4, LILRA5, LILRA6, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, LITAF, LT A, LTB4R, LTB4R2, LTBR, LTF, LY96, MAF, MALT1, MAP4K1, MAP4K2, MAP4K4, MAPK1, MAPK11, MAPK14, MAPKAPK2, MARCO, MASP1, MASP2, MBL2, MBP, MCL1, MIF, MME, MRI, MRC1, MS4A1, MSR1, MUC1, MX1, MYD88, NCAM1, NCF4, NCR1, NFATC1, NFATC2, NFATC3, NFIL3, NFKB1, NFKB2,NFKBIA, NFKBIZ, NLRP3, NODI, N0D2, NOS2, NOTCH1, NOTCH2, NT5E, OAZ1, PAX5, PDCD1, PDCD1LG2, PDCD2, PDGFB, PDGFRB, PEC AMI, PIGR, PLA2G2A, PLA2G2E, PLAAT4, PLAU, PLAUR, PML, POLR1B, POLR2A, POU2F2, PPARG, PPBP, PPIA, PRDM1, PRF1, PRKCD, PSMB10, PSMB5, PSMB7, PSMB8, PSMB9, PSMC2, PSMD7, PTAFR, PTGER4, PTGS2, PTK2, PTPN2, PTPN22, PTPN6, PTPRC, PYCARD, RAFI, RAG1, RAG2, RELA, RELB, RORC, RPL19, RTRAF, RUNX1, S100A8, S100A9, S1PR1, SDHA, SELE, SELL, SELPLG, SERPING1, SH2D1A, SIGIRR, SKI, SLAMF1, SLAMF6, SLAMF7, SLC2A1, SMAD3, SMAD5, SOCS1, SOCS3, SPP1, SRC, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, STING1, SYK, TAGAP, TALI, TAPI, TAP2, TAPBP, TBK1, TBP, TBX21, TCF4, TCF7, TFRC, TGFB1, TGFBI, TGFBR1, TGFBR2, THY1, TICAM1, TIGIT, TIRAP, TLR1, TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, TNF, TNFAIP3, TNFAIP6, TNFRSF10C, TNFRSF11A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF17, TNFRSF1B, TNFRSF4, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13B, TNFSF15, TNFSF4, TNFSF8, TOLLIP, TP53,TRAF1, TRAF2, TRAF3, TRAF4, TRAF5, TRAF6, TUBB, TYK2, UBE2L3, VCAM1, VTN, XBP1, XCL1, XCR1, ZAP70, ZBTB16, ZEB1 and sCTLA4.

[0071] Step ii) of determining the vaccine potential of the composition will then, in connection with this step id), specify the vaccine potential of the composition.

[0072] Preferably, genes related to the immune system are cytokines.

[0073] Step ii) of determining the vaccine potential of the composition will then, in connection with this step id), determine the inflammatory potential associated with this same composition.

[0074] Examples of usable cytokines include interleukins and their receptors. Examples of interleukins include IL-1A, IL-1B, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17A, IL-17C, IL-17F, IL-19, IL-21, IL-22, IL-23, IL-27, IL-31 and IL-33, and examples of interleukin receptors include IL-10RA, IL-10RB, IL-1R1, IL-5RA (CD125) and IL-9R.

[0075] Chemokines are another usable cytokine. These chemotactic cytokines control the migration patterns and positioning of immune cells, as well as their receptors. Examples of cytokines include C5, Eotaxin, MCP-4, TARC, MCP-1, MIP-3A, CCL22, CCL23, MIP-1B, RANTES, MCP-3, MCP-2, CX3CL1, IL8RA, INP10, L8RB, and CXCL3. Chemokine receptors include CCL13 (MCP-4), CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CX3CR1, CXCR1, and CXCR2.

[0076] It should be noted that other cytokines (besides interleukins and chemokines) are also potential markers of inflammation. Examples of such cytokines include MCP-1, GM-CSF, TNFSF5, MCSF, GCSF, TNFSF6, IFNA2, IFNG, TNFA, TNFB, MIF, NAMPT, TRAIL, and IFNA1.

[0077] Advantageously, cytokines are chosen from GM-CSF, MIP-la, MCP-1, IL-2, IL-4, IL-6, IL-8, IL-13, IL-12, IL-15, IL-16, MIP-3a, IP-10, MIP-la, MIP-lb, MDC, IL-27, and Eotaxin-3.

[0078] The cytokine expression profile can be determined within the skin explant, the culture medium, or even within the matrix.

[0079] Now, the inventors have highlighted that the cytokine expression profile within the matrix showed both greater diversity and higher levels of expression.

[0080] Advantageously, therefore, the determination of the cytokine expression profile is done within the skin explant matrix.

[0081] According to a preferred embodiment, the process further includes a step id) determination of the level of mast cell degranulation within the skin explant.

[0082] Step ii) of determining the vaccine potential of the composition will then, in connection with this step ie), determine again the inflammatory potential associated with this same composition.

[0083] Step ie) of determining the level of mast cell degranulation can be carried out using techniques well known to those skilled in the art. Techniques usable for this step include ELISA or colorimetric techniques allowing the measurement of the presence of inflammatory mediators contained in mast cell granules, such as histamine or tryptase, or secreted de novo such as lipid mediators or cytokines / chemokines, or even fluorescence, immunofluorescence or fluorochrome techniques specific to mast cell granules.

[0084] Advantageously, this step ie) is carried out within a maximum of 6 hours following the administration step ie), preferably within a maximum of 4 hours.

[0085] According to a preferred embodiment, step ie) of determining the level of mast cell degranulation within the skin expiry is carried out by fluorescence analysis.

[0086] Advantageously, this step ie) of determining the level of mast cell degranulation uses avidin.

[0087] Avidin is indeed a glycoprotein that binds very specifically to heparin contained in mast cell granules (THARP et al., J. Histochem. Cytochem., vol. 33, pp. 27-32, 1985). Thus, during the degranulation process, the granules, once they are externalized, become directly accessible to avidin. Now, in the case of tissue fixation, the intracellular granules are accessible to avidin once tissue permeabilization occurs. This Avidin can be complexed with a fluorochrome (avidin-FITC, avidin-Alexa488, avidin-sulfurhodamine 101, or any other fluorescent molecule) or with a bioluminescent molecule. It is also now possible to use avidin alone (uncomplexed) and in combination with a complementary molecule. Examples of such molecules include biotin complexed with a fluorochrome, a bioluminescent molecule, or any other identifiable molecule.

[0088] Now, determining the level of mast cell degranulation can utilize other markers, particularly those of the nucleus or plasma membrane, to facilitate the identification of extemalized granulocytes from mast cells. It will also be possible to measure tryptase, histamine, beta-hexosaminidase, chymase, or any other molecules preformed within mast cell granules and released during degranulation in the culture medium.

[0089] Typically, the determination of the level of mast cell degranulation within the skin expiry can be carried out by following the protocol described in GAUDENZIO et al. (J. Clin. Invest., vol.126, p:3981-3998, 2016)

[0090] Advantageously, step ie) of determining the level of mast cell degranulation will be carried out on at least one histological section taken from the skin expiry.

[0091] To achieve this, well-known immunohistochemical methods can be used, which involve fixing a skin Texplant, embedding the expiant (e.g., paraffin, OCT, EPON) before preservation, and finally preparing histological sections of the embedding block. Details of such methods are described, for example, in "Immunohistochemistry: Basics and Methods" by Igor Buchwalow (Springer Publishers).

[0092] Usable histological sections can be very thick, up to 500 µm. Advantageously, the histological section will thus have a thickness between 1 and 500 µm. It is now also possible to use sections with more conventional dimensions, with a thickness between 2 and 25 µm.

[0093] Regarding the determination of the mast cell granulation level within Texplant itself, for each identified mast cell, it is determined whether it is associated with weak, moderate, or strong degranulation, followed by the proportion (percentage) of mast cells associated with each of these types of degranulation (weak, moderate, and strong). The level of degranulation can also be analyzed automatically using image analysis software, a computer algorithm, or artificial intelligence techniques known as "machine learning" or "deep learning".

[0094] In detail, a mast cell with a low level of degranulation corresponds to a mast cell with 0 to 2 granules around it (or a cell with a smooth outline); a mast cell with a moderate level of degranulation corresponds to a mast cell with 3 to 6 granules around it (or a cell with an outline with a granular appearance); and a mast cell with a high level of degranulation corresponds to a mast cell with more than 6 granules around it (or a cell with an exposed shape).

[0095] Thus, it will be possible to determine if the composition presents an inflammatory potential with regard to the percentage of mast cell degranulation as determined by the outcome of step ie).

[0096] Thus, a composition associated with a proportion of mast cells exhibiting more than 50% a low level of degranulation and / or less than 10% a high level of degranulation will present a low, or even zero, inflammatory potential.

[0097] Conversely, a composition associated with a proportion of mast cells exhibiting a high level of degranulation in more than 50% will present a high inflammatory potential.

[0098] The following examples are given solely as an illustration of the object of the present invention and in no way constitute a limitation. Examples

[0099] 1 - Preparation of skin expiants [000100] Skin expiants are prepared from complete skin samples taken from different donors, which samples included the epidermis, dermis, and hypodermis (1.5 to 2 cm). The expiants (epidermis, dermis, and hypodermis) were then cut using a metal punch to obtain cylinders of 11 to 20 mm in diameter, in which the hypodermis thickness is adjusted to the desired value (0.5 to 1 cm). Finally, these excipients were kept afloat in a buffered saline solution until the "inclusion" step in the solidified matrix. This inclusion step was performed using a process similar to that used for the NATIVESKIN™ model. Briefly, the skin Texplant is carefully placed onto an insert (MILLICELL™ 8-well cup) with a porous membrane (PET, 1 µm porosity) at the bottom, containing a solution derived from blood plasma treated with an anticoagulant agent with reversible properties in the presence of calcium ions (sodium citrate). This solution contains 42% blood plasma, 50% of a 0.9% NaCl solution, 8% of a 1% CaC12 saline solution, an anti-fibrinolytic agent (tranexamic acid or aprotinin), and 0.7% low melting point molten agarose (Agarose LMP GIBCOBRL, LIFE TECHNOLOGIES) (oven melted at 65.5 °C).The antifibrinolytic agent functions to inhibit enzymes that can degrade the plasma matrix, these enzymes being secreted by the skin explant, and thus to maintain the integrity of the explant. [000101] 2-Skin antigen-presenting cells and expiratory cells [000102] 2.1 - Identification of antigen-presenting cells within the skin explant [000103] The presence of antigen-presenting cells within the explant was analyzed during culture and in the days following culture using several techniques: immunohistochemistry coupled with artificial intelligence (multiplexed imaging), single-cell transcriptomic analysis, and flow cytometry. Single-cell transcriptomic analysis revealed the presence, in the model and compared to human skin, of comparable proportions of immune cells (expressing PTPRC), stromal cells (expressing VIM), melanocytes (expressing MLANA), keratinocytes (expressing KRT14 and KRT1), and adipocytes over a 10-day period. Any changes in the transcriptome of all these cells were investigated over time.Of the 2,000 genes detected during the experiment, only a slight variation of just 55 genes in the immune compartment was detected between day 0 and day 5 of culture, with a return to normal between day 5 and day 10 of culture. These data indicate that the cells... The structural and immune components contained in the HYPOSKIN models remain phenotypically and functionally stable for a period of at least 10 days. [000104] In conclusion, the results unexpectedly showed that antigen-presenting cells in the skin expiry exhibit a number and diversity similar to those observed in in vivo skin. Moreover, the results also showed that this number and diversity of antigen-presenting cells are maintained from the first to the tenth day of culture. [000105] 2.2-Demonstration of maturation of antigen-presenting cells within the skin explant [000106] In view of the previous result, the inventors questioned the maturation capacity of the antigen-presenting cells within the skin explant. [000107] Also, and to test this maturation capacity, several techniques were used: immunohistochemistry coupled with artificial intelligence (multiplexed imaging), single-cell transcriptomic analysis and flow cytometry. [000108] Here again and unexpectedly, the results showed that in addition to preserving their number and diversity, the antigen-presenting cells also exhibit an intact maturation capacity. [000109] Therefore, the skin explant can be used to test the ability of an antigenic composition to activate antigen-presenting cells. At the same time, and as previously demonstrated by the inventors, it is possible to test the inflammatory potential associated with this same composition. [000110] 3 - Confirmation of the vaccine potential of the INFLUVAC TETRA composition [000111] 125 pL of INFLUVAC TERTR vaccine solution were injected into the adipose tissue of skin explants from 3 separate donors using a syringe and a 27G needle 12 mm long. As a negative control, 100 pL of water was injected into the adipose tissue of skin explants from the same donors. [000112] The expiants were then cultured (incubator at 37°C, 5% CO2 and water-saturated atmosphere) for 8h, 24h and 48h. [000113] Hematoxylin and eosin staining was performed on skin excipients from each donor before injection and 48 hours after injection of water or the vaccine composition. Simultaneously, the presence of any DNA fragmentation was tested on these same skin excipients. [000114] The results showed, for the 3 donors, no alteration of cellular integrity 48h after injection of the vaccine composition. [000115] After evaluating the stability and viability of the model during the study, cytokine production by the models was investigated. To obtain optimal results, the assay was performed on the culture medium, matrix, and lysate of the models injected with water and vaccine at 8 hours of culture for the three donors in the study. [000116] Many cytokine concentration values ​​are not reported for the lysate because their concentration is below the detection limit of the MSD instrument. Regarding the assay on the culture medium, it allows for the measurement of the concentration of most cytokines in the panel, but in significantly lower quantities than the assay on the matrix, even though the concentration trends are the same for both assays. Consequently, the matrix will be used for future cytokine assays, as it allows for the detection of most cytokines at sufficient concentrations. [000117] Following optimization of the MSD assay, the concentrations of 36 cytokines were measured in the matrix of study models. The uninjected models appeared to be the least inflamed and generally exhibited the lowest cytokine concentrations. At 8 hours post-injection, a slight increase in cytokine concentration was observed. A marked increase in cytokine production was observed in the 3 donors tested 24 hours post-injection, with higher cytokine concentrations in the vaccinated models, notably IFN-γ, TNF-α, IL-α, IP-10, eotaxin-3, IL-12p40, IL-13, IL-15, IL-16, MCP-4, MIP-α, MIP-β, MIP-3α, IL-β, GM-CSF, MCP-1, and T ARC. [000118] Finally, cytokine concentration increases slightly 48 hours after injection, particularly in vaccinated models. Overall, a biological response is observed following vaccination through the production of cytokines and chemokines. related to immune system activation in models over time, notably with a peak 24 hours after injection [000119] In order to determine the presence of antigen-presenting cells, skin expiants from each of the donors before injection, 8h, 24h and 48h after injection of water or vaccine composition were cryopreserved at -80°C for immunohistochemical analysis, or embedded in paraffin for mast cell degranulation analysis. [000120] Ciyopreserved sections were then labeled with different antibodies specific to antigen-presenting cells (anti CD45, CD207, CDlc, CD40, CCR7, CD80, CD86, CD83, and HLA-DR). [000121] Analysis of these sections showed that injection of the vaccine composition leads to the activation of antigen-presenting cells (APCs) within the expiry, as well as the migration of a number of them. Consequently, the results therefore show that the administered vaccine is associated with the establishment of adaptive immunity. [000122] Paraffin-embedded sections were used simultaneously to determine the level of mast cell degranulation within the tissue under different conditions. This was done by labeling with avidin coupled to a fluorochrome, which allows for the detection of mast cell granules. The first step involved deparaffinizing and rehydrating the fixed, paraffin-embedded sections. The sections were incubated for 30 minutes at room temperature in citrate buffer pH 6, then saturated and permeabilized for 40 minutes at 37°C with a 0.1% goat serum and Triton solution. The sections were then incubated for one hour at room temperature in a humid chamber with 5 pg / mL of avidin-sulforhodamin 101 (Avidin TEXAS RED; MERCK). Cell nuclei are then stained by incubating the sections with DAPI (D9542, SIGMA) at 1 / 1000 for 3 minutes at room temperature.Mounting medium is added and a coverslip is placed on the sections. The slides are then analyzed under a fluorescence microscope to determine the level of mast cell degranulation in the different excipients. [000123] The results of these degranulation experiments are presented in Table 3. [000124] [Table 3] [000125] The results made it possible to determine the level of degranulation of the mast cells identified in the samples and, after integration, to deduce the inflammatory potential of the injected composition. In this case, the results show that the administered vaccine is not associated with an inflammatory risk due to mast cell degranulation. [000126] 4-Confirmation of the vaccine potential of the INFLUVAC TETRA composition [000127] Analysis of the INFLUVAC TETRA vaccine composition revealed that this vaccine induces the expression of a cytokine signature indicative of cutaneous immune system activation, including the expression of GM-CSF, MIP-1a, MCP-1, IL-2, IL-4, IL-6, IL-8, IL-13, IL-12, IL-15, IL-16, MIP-3a, IP-10, MIP-1a, MIP-1b, MDC, IL-27, and Eotaxin-3 between 8 and 24 hours of culture. Using multiplex imaging, it was demonstrated that the vaccine induces the activation of dermal dendritic cells and Langerhans cells via an increase in the expression of the maturation / activation markers CD40, CCR7, CD80, CD86, CD83, and HLA-DR.

Claims

Claims: An in vitro method for determining the vaccine potential of a composition comprising the steps of: ia) transcutaneous administration of the composition to a skin expiant, including the epidermis, dermis, and epidermal appendages, as well as a hypodermis at least 5 millimeters thick; ib) determination of the activation status of antigen-presenting cells within the skin expiant; and ii) determination of the vaccine potential of the composition. The method according to claim 1, characterized in that the antigen-presenting cells are selected from dermal cDC1 cells, dermal cDC2 Langerin cells, dermal cDC2 Langerin cells, and Langerhans cells. The method according to claim 1 or 2, characterized in that step ia) consists of subcutaneous or transdermal administration of a composition comprising the substance into a skin expiant.The method according to any one of claims 1 to 3, characterized in that an antigen-presenting cell is considered to be activated when at least 2 activation markers are overexpressed in that cell, which activation markers are chosen from those described in Table 2. [Table 2] The method according to claim 4, characterized in that the overexpression of an activation marker corresponds to an increase in its expression of at least 20%. The method according to any one of claims 1 to 5, characterized in that step ii) of determining the vaccine potential of the composition is carried out with regard to the proportion of antigen-presenting cells activated at the end of step ia), with: • a composition associated with an activation of at most 10% of the antigen-presenting cells will have a low, or even zero, vaccine potential; • A composition associated with the activation of at least 40% of antigen-presenting cells will exhibit high vaccine potential. The method according to claim 1 or 2, characterized in that it further comprises a step ic) of determining the possible migration of antigen-presenting cells within the skin explant. The method according to any one of claims 1 to 3, characterized in that it further comprises a step id) of determining the cytokine expression profile within the skin explant and in that step ii) further enables the determination of the inflammatory potential associated with this same composition. The method according to the preceding claim, characterized in that the determination of the cytokine expression profile is performed within the skin explant matrix.The method according to any one of claims 1 to 3, characterized in that it further comprises a step ie) of determining the level of mast cell degranulation within the skin explant and in that step ii) further allows determining the inflammatory potential associated with this same composition.